Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for ripretinib

  1. Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (TA1146)

    Evidence-based recommendations on ripretinib (Qinlock) for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors in adults.

    Technology appraisal guidance
    Published
    28 April 2026

    Sections for TA1146

  2. Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)

    This guidance has been updated and replaced by NICE technology appraisal guidance on ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (TA1146).

    Withdrawn guidance